Viridian Therapeutics, Inc. (NASDAQ:VRDN) is Cutter Capital Management LP's 10th Largest Position

Cutter Capital Management LP boosted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 628,677 shares of the company's stock after acquiring an additional 110,000 shares during the quarter. Viridian Therapeutics accounts for 4.9% of Cutter Capital Management LP's portfolio, making the stock its 10th biggest holding. Cutter Capital Management LP owned 0.79% of Viridian Therapeutics worth $12,052,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Braidwell LP purchased a new position in Viridian Therapeutics in the 4th quarter worth about $654,000. Brevan Howard Capital Management LP purchased a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $258,000. Bayesian Capital Management LP increased its stake in shares of Viridian Therapeutics by 99.2% in the 4th quarter. Bayesian Capital Management LP now owns 25,700 shares of the company's stock valued at $493,000 after purchasing an additional 12,800 shares in the last quarter. Bank of America Corp DE grew its position in shares of Viridian Therapeutics by 36.5% in the fourth quarter. Bank of America Corp DE now owns 247,107 shares of the company's stock valued at $4,737,000 after purchasing an additional 66,138 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $3,908,000.

Wall Street Analyst Weigh In

VRDN has been the topic of several research analyst reports. The Goldman Sachs Group cut their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank of Canada cut their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday. JMP Securities dropped their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday. Finally, Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $35.18.

Viridian Therapeutics Trading Down 1.9 %

Viridian Therapeutics stock traded down $0.24 during trading hours on Friday, reaching $12.54. 655,726 shares of the company's stock were exchanged, compared to its average volume of 1,195,808. The firm's 50 day simple moving average is $13.71 and its 200 day simple moving average is $17.53. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.02 billion, a PE ratio of -2.91 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. The company's quarterly revenue was up .0% compared to the same quarter last year. Research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.